CP-154526

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N4
Molecular Weight	364.527
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CC)C1=NC(C)=NC2=C1C(C)=CN2C3=C(C)C=C(C)C=C3C

InChI

InChIKey=FHQYJZCJRZHINA-UHFFFAOYSA-N

InChI=1S/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9171885
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/10367986 | http://adisinsight.springer.com/drugs/800007484 | https://www.ncbi.nlm.nih.gov/pubmed/18591672

CP 154526 hydrochloride is a selective, non-peptide corticotropin releasing hormone receptor 1 (CRF1) antagonist. CP 154526 readily penetrates the CNS following peripheral administration. In the clinic, CP-154,526 may have important therapeutic utility in treating depression and anxiety as well as other diseases where excessive stimulation of CRF receptors contributes to pathology. The CRF1 receptor antagonist CP-154,526 attenuated the acquisition and prevented the expression of EtOH-induced psychomotor sensitization.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Corticotropin releasing factor receptor 1 8 Target ID: CHEMBL1800 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8816826	Antagonist 2849		2.7 nM [Ki]
Corticotropin releasing factor receptor 2 1 Target ID: CHEMBL4069 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8816826	Antagonist 2849		10.0 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8874139 https://www.ncbi.nlm.nih.gov/pubmed/9171885 https://www.ncbi.nlm.nih.gov/pubmed/9694527	Primary	Preclinical	Unknown Approved Use Unknown
Depression 240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10367986 https://www.ncbi.nlm.nih.gov/pubmed/9171885	Primary	Preclinical	Unknown Approved Use Unknown
Fever 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8874139	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.	1997-05-23	9171885
Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.	1997-03-26	9105872
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.	1996-09-17	8816826
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.	1996-08-08	8874139

Patents

Sample Use Guides

In Vivo Use Guide

30 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

CP 154526 completely blocked the activation of adenylate cyclase caused by 100 nM oCRF with an apparent Ki of 3.7 nM

Name

Type

Language

CP-154,526

Preferred Name

English

CP-154526

Common Name

English

7H-PYRROLO(2,3-D)PYRIMIDIN-4-AMINE, N-BUTYL-N-ETHYL-2,5-DIMETHYL-7-(2,4,6-TRIMETHYLPHENYL)-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID201027582